Literature DB >> 15993589

Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.

David Y W Lee1, Vishnu V R Karnati, Minsheng He, Lee-Yuan Liu-Chen, Leelakrishna Kondaveti, Zhongze Ma, Yulin Wang, Yong Chen, Cecile Beguin, William A Carlezon, Bruce Cohen.   

Abstract

Salvinorin A is the most potent naturally occurring opioid agonist yet discovered with high selectivity and affinity for kappa-opioid receptor. To explore its structure and activity relationships, a series of salvinorin A derivatives modified at the C2 position were prepared and studied. These salvinorin A derivatives were screened for binding and functional activities at the human kappa-opioid receptor. Compound 4, containing a methoxymethyl group at the 2-position, was a full kappa-agonist with an EC50 value at 0.6 nM, which is about 7 times more potent than salvinorin A.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993589     DOI: 10.1016/j.bmcl.2005.05.048

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  34 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

2.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

3.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

Review 4.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  Autoxidation of salvinorin A under basic conditions.

Authors:  Thomas A Munro; Glenn W Goetchius; Bryan L Roth; Timothy A Vortherms; Mark A Rizzacasa
Journal:  J Org Chem       Date:  2005-11-25       Impact factor: 4.354

6.  Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity.

Authors:  Gianfranco Fontana; Giuseppe Savona; Benjamín Rodríguez; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Tetrahedron       Date:  2008-12-20       Impact factor: 2.457

7.  Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Authors:  Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin
Journal:  Bioorg Med Chem       Date:  2007-10-24       Impact factor: 3.641

8.  Revised structure of deacetyl-1,10-didehydrosalvinorin G.

Authors:  Zhongze Ma; David Y W Lee
Journal:  Tetrahedron Lett       Date:  2007-07-30       Impact factor: 2.415

9.  CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.

Authors:  Donna L McGovern; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
Journal:  J Mol Graph Model       Date:  2010-01-04       Impact factor: 2.518

10.  (2S,4aR,6aR,7R,9S,10aS,10bR)-7-Carb-oxy-2-(3-fur-yl)-6a,10b-dimethyl-4,10-dioxoperhydro-benzo[f]isochromen-9-yl acetate.

Authors:  Paulo Carvalho; Lukasz M Kutrzeba; Jordan K Zjawiony; Mitchell A Avery
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.